# Sernivo - (0.05%; Spray, Topical)

| | | | |
|---|---|---|---|
| **Generic Name** | Betamethasone Dipropionate | **Innovator** | Encore |
| **Dosage** | 0.05%; Spray, Topical | **Branded US Sales** | Less Than $1000 mn |
| **Probable FTF** | Less Than 5 | **Known Para IV Filers** | Less Than 5 |
| **Other ANDA developers** | None | **Tentative Approvals** | Less Than 5 |
| **Final Approvals** | Less Than 5 | **Generic Launches** | None |
| **Indication** | Indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older. | | |
| **Complexities** | Yes | | |

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

## Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

## Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

## Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.